Safety and Immunogenicity of SYS6017 in Healthy Participants Aged 40 Years or More

NCT06954818 | Not Yet Recruiting Phase 1

• 1 other identifier: SYS6017-001
• Study Type: interventional
• Target: 200
• Locations: 0 countries
• Sites: N/A

Brief Summary

Herpes zoster is caused by the reactivation of latent varicella-zoster virus (VZV) which stays in latency after its primary infection. Immunosenescence contributes significantly to elevating morbidity associated with aging. Vaccination plays a key role in reducing the disease burden of zoster and the associated complications. This randomized, observer-blind, placebo-controlled, adaptive phase 1 trial aims to evaluate the safety and immunogenicity of an investigational zoster mRNA vaccine in healthy participants aged 40 years or more.

Conditions

Herpes Zoster

Outcome Measures

Primary Outcomes (2)

• solicited adverse events

  within 14 days post each vaccination

• unsolicited adverse events

  within 30 days post each vaccination

Secondary Outcomes (5)

• serious adverse events

  from the first vaccination through 12 months post the second vaccination

• adverse events of special interest

  from the first vaccination through 12 months post the second vaccination

• pregnancy events

  from the first vaccination through 12 months post the second vaccination

• anti-gE antibody geometric mean concentration, geometric mean fold increase and seroconversion rate.

  before the second vaccination, 14 and 30 days post the second vaccination

• anti-VZV antibody geometric mean titer, geometric mean fold increase and seroconversion rate.

  before the second vaccination, 14 and 30 days post the second vaccination

Study Arms (6)

Investigational vaccine of Dosage A

EXPERIMENTAL

Biological: A zoster mRNA vaccine SYS6017

Investigational vaccine of Dosage B

EXPERIMENTAL

Biological: A zoster mRNA vaccine SYS6017

Investigational vaccine of Dosage C

EXPERIMENTAL

Biological: A zoster mRNA vaccine SYS6017

Investigational vaccine of Dosage D

EXPERIMENTAL

Biological: A zoster mRNA vaccine SYS6017

Investigational vaccine of Dosage E

EXPERIMENTAL

Biological: A zoster mRNA vaccine SYS6017

Placebo

PLACEBO COMPARATOR

Other: Placebo

Interventions

A zoster mRNA vaccine SYS6017 BIOLOGICAL

SYS6017 is an investigational lipid nanoparticle (LNP)-coated mRNA vaccine encoding the glycoprotein E (gE) of VZV, and indicated for active immunization for the prevention of zoster caused by the reactivation of latent VZV.

Investigational vaccine of Dosage A; Investigational vaccine of Dosage B; Investigational vaccine of Dosage C; Investigational vaccine of Dosage D; Investigational vaccine of Dosage E

Placebo OTHER

saline solution

Placebo

Eligibility Criteria

• Age: 40 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \. Healthy participants aged 40 years or more;
• \. Be able to understand the study procedures and comply with the requirements of the protocol for the scheduled visits, voluntarily consent to participate in the study and sign the informed consent form (ICF);
• \. Being in good health at the discretion of investigators based on medical history inquiry, physical examination, laboratory test and electrocardiograph examination;
• \. For female participants of childbearing potential: no sexual activity or used effective contraceptive methods within one menstrual cycle before enrollment; no pregnancy plans and agree to used effective contraceptive methods with 8 months after enrollment.

You may not qualify if:

• \. History of zoster;
• \. History of vaccination with varicella vaccine or zoster vaccine (including investigational vaccine);
• \. Axillary temperature ≥ 37.1℃ on the day of enrollment or within 24 h before enrollment;
• \. Have abnormal test or examination result that is of Grade 1 (inclusive) or more in accordance with the Guidelines for Adverse Event Grading Standards for Clinical Trials of Preventive Vaccines (2019) issued by China National Medical Products Administration or other applicable adverse event grading standards referred in the protocol;
• \. History of allergy to any component of the investigational vaccine, or history of severe allergic reaction (including but not limited to anaphylaxis, allergic laryngeal edema, Henoch-Schonlein purpura, thrombocytopenia purpura or Arthus reaction) to vaccines or medicines;
• \. History of myocarditis, pericarditis, or idiopathic cardiomyopathy, or any condition that would increase the risk of myocarditis or pericarditis;
• \. History of demyelinating diseases, including but not limited to Guillain-Barré syndrome, multiple sclerosis, ophthalmoneuromyelitis, acute disseminated encephalomyelitis, etc.
• \. Current epilepsy or convulsion, severe neurological or psychiatric disorders;
• \. Have contraindications to intramuscular injection, e.g., diagnosed thrombocytopenia, any coagulation disorders, or current treatment with anticoagulants, etc;
• \. Active malignant tumor, malignant tumor without adequate treatment, malignant tumor with a potential risk of recurrence during the study;
• \. Active, unstable, severe or uncontrolled cardiovascular and cerebrovascular diseases, thrombotic diseases, blood and lymphatic system diseases, liver and kidney diseases, respiratory diseases, metabolic diseases, musculoskeletal diseases, autoimmune diseases, etc;
• \. Have diagnosed immunocompromise or immunosuppression, congenital or functional asplenia, or splenectomy;
• \. Have received immunosuppressants, immunostimulants, or other immunomodulatory medicines (e.g., corticosteroids, ≥ 20 mg/d prednisone or equivalent) for a long time (defined as 14 days or more), within 6 months before enrollment, or planning to receive the aforementioned medicines during the study; inhaled and topical steroids are allowed;
• \. Have received whole blood, plasma, serum, immunoglobulins, or monoclonal antibodies within 3 months before enrollment, or planning to receive these products during the study;
• \. Blood donation or blood loss ≥ 450 mL within 1 month before enrollment, or planning to donate blood during the study;

Sponsors & Collaborators

• CSPC Megalith Biopharmaceutical Co.,Ltd.: lead

MeSH Terms

Conditions

Herpes Zoster

Condition Hierarchy (Ancestors)

Varicella Zoster Virus Infection; Herpesviridae Infections; DNA Virus Infections; Virus Diseases; Infections

Central Study Contacts

Clinical Trials Information Group officer

CONTACT

86-0311-69085587; ctr-contact@cspc.cn

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: The participants are to be randomly assigned to the investigational vaccine or the placebo.

Study Record Dates

• First Submitted: April 24, 2025
• First Posted: May 2, 2025
• Study Start: May 10, 2025
• Primary Completion: December 10, 2025
• Study Completion (Estimated): November 10, 2026
• Last Updated: May 8, 2025

Record last verified: 2025-05